Schering-Plough buys Millennium's stake in heart drug

Schering-Plough is buying out Millennium Pharmaceuticals' share of the heart drug Integrilin for a minimum of $250.5 million. Of that, $35.5 million will come as an upfront payment with a minimum of $85 million per year for the next two years in royalty payments. Millennium will also pocket $45 million to $50 million for stockpiles of the pharmaceutical.

"Acquiring the balance of US rights to Integrilin will give us direct control of this important therapy in its largest market. This is yet another long-term action we are taking to increase our importance to health providers and patients and to become a global leader in the very important area of cardiac care," said Fred Hassan, Schering-Plough chairman and CEO.

- read this story from TheStreet.com for more

PLUS: Cambridge, Massachusetts-based Millennium swiftly announced that the revised deal with Schering-Plough would lead to the elimination of some 200 jobs. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.